U.S. FDA approves 1st new Alzheimer’s drug in nearly 20 years


Sumary of U.S. FDA approves 1st new Alzheimer’s drug in nearly 20 years:

  • American government health officials on Monday approved the first new drug for Alzheimer disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease..
  • The decision, which could impact millions of older Americans and their families, is certain to spark disagreements among physicians, medical researchers and patient groups..
  • Dementia, Alzheimer most common disease associated with COVID-19 deaths, says StatCan The new drug, which Biogen developed with Japan Eisai Co., did not reverse mental decline, only slowing it in one study..
  • Under terms of the so-called accelerated approval, the FDA is requiring the drugmaker to conduct a follow-up study to confirm benefits for patients..
  • If the study fails to show effectiveness, the FDA could pull the drug from the market, though the agency rarely does so..
  • A preliminary analysis by one group found that the drug would need to be priced $2,500 to $8,300 per year to be a good value based on the “small overall health gains”.
  • The pharmaceutical industry drug pipeline has been littered for years with failed Alzheimer treatments, representing billions in research costs..
  • Researchers don’t fully understand what causes Alzheimer but there broad agreement that the brain plaque targeted by aducanumab is just one factor….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.